Cancer Chemotherapy and Pharmacology

, Volume 63, Issue 6, pp 1161–1163 | Cite as

Isolated molecular relapse in FIP1L1-PDGFRα hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose

  • Massimo Breccia
  • Daniela Cilloni
  • Laura Cannella
  • Caterina Stefanizzi
  • Agostino Tafuri
  • Angelo Fama
  • Michelina Santopietro
  • Giuseppe Saglio
  • Giuliana Alimena
Short Communication

Abstract

Imatinib is the treatment of choice for FIP1L1-PDGFRα (F/P+) positive myeloproliferative neoplasms, but little is known about optimal dose and duration of treatment to maintain complete molecular remission once achieved. We describe a case of F/P+ patients who started imatinib and reached a molecular remission, but did relapse after 15 months of therapy for poor adherence to therapy, and re-obtained remission only with standard dose of 400 mg/day. We reviewed the literature and highlights the need of quantitative molecular procedures to modulate imatinib dose.

Keywords

Imatinib Hypereosinophilic syndrome FIPL1-PDGFR-alpha Molecular remission 

References

  1. 1.
    Chusid MJ, Dale DC, West BC, Wolff SM (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine 54:1–27PubMedCrossRefGoogle Scholar
  2. 2.
    Gotlib J, Cools J, Malone JM, Schrier SL, Gilliland DG, Coutre SE (2004) The FIP1L1-PDGFRa fusion tyrosine kinase in hyper eosinophilic syndrome and chronic eosinophilic leukaemia: implications for diagnosis, classification and management. Blood 103:2879–2891PubMedCrossRefGoogle Scholar
  3. 3.
    Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, Metcalfe DD, Dunbar C, Nutman TB (2004) Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103:473–478PubMedCrossRefGoogle Scholar
  4. 4.
    Schaller JL, Burkland GA (2001) Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med 3:9Google Scholar
  5. 5.
    Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, De Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G (2007) The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRa positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92:1173–1179PubMedCrossRefGoogle Scholar
  6. 6.
    Helbig G, Stella-Holowiecka B, Grosicki S, Bober G, Krawczyk M, Wojnar J, Reiter A, Hochhaus A, Holowiecki J (2006) The results of imatinib therapy for patients with primary eosinophilic disorders. Eur J Haematol 76:535–536PubMedCrossRefGoogle Scholar
  7. 7.
    Cilloni D, Messa F, Martinelli G, Gottardi E, Arruga F, Defilippi I, Carturan S, Messa E, Fava M, Giugliano E, Rosso V, Catalano R, Merante S, Nicoli P, Rondomi M, Ottaviani E, Soverini S, Tiribelli M, Pane F, Baccarani M, Saglio G (2007) WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukaemia. Leukemia 21:1442–1450PubMedCrossRefGoogle Scholar
  8. 8.
    Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14–22PubMedCrossRefGoogle Scholar
  9. 9.
    Cools J, De Angelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG (2003) A tyrosine kinase created by fusion of the PDGFRa and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New Engl J Med 348:1201–1214PubMedCrossRefGoogle Scholar
  10. 10.
    Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyi AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald GW, Tefferi A (2006) FIP1L1-PDGFRa in eosinophilic disorders: prevalence in routine clinical practice, long term experience with imatinib therapy and a critical review of the literature. Leuk Res 30:965–970PubMedCrossRefGoogle Scholar
  11. 11.
    Tefferi A, Patnaik MM, Pardanani A (2006) Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 133:468–492PubMedCrossRefGoogle Scholar
  12. 12.
    Klion AD, Robyn J, Maric I, Fu W, Schmid I, Lemery S, Noel P, Law MA, Hatsell M, Talar-Williams C, Fay MP, Dunbar CE, Nutman TB (2007) Relapse following discontinuation of imatinib mesylate therapy for FIP1L1-PDGFRa-positive chronic eosinophilic leukaemia: implications for optimal dosing. Blood 110:3352–3356CrossRefGoogle Scholar
  13. 13.
    Helbig G, Holowiecka SB, Majewski M, Calbecka M, Gajkowska G, Klimkiewicz R, Moskwa A, Grzegorczyk J, Lewandowska M, Holowiecki J (2008) A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRa-expressing patients. Br J Haematol 141:200–204PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Massimo Breccia
    • 1
    • 3
  • Daniela Cilloni
    • 2
  • Laura Cannella
    • 1
  • Caterina Stefanizzi
    • 1
  • Agostino Tafuri
    • 1
  • Angelo Fama
    • 1
  • Michelina Santopietro
    • 1
  • Giuseppe Saglio
    • 2
  • Giuliana Alimena
    • 1
  1. 1.Department of Cellular Biotechnology and HematologyUniversity La SapienzaRomeItaly
  2. 2.Department of Clinical and Biological Sciences of the University of TurinSan Luigi HospitalOrbassanoItaly
  3. 3.Department of Human Biotechnology and HematologyRomeItaly

Personalised recommendations